Small molecule · Inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) · developed by Novartis
Ribociclib is a kinase inhibitor of cyclin-dependent kinases 4 and 6, which are activated by D-cyclins and drive cell cycle progression through phosphorylation of the retinoblastoma protein. By blocking these kinases, it causes G1 phase arrest and reduced proliferation. It is studied in early breast cancer.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 1, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05827081 | Phase 3 | Early Breast Cancer | Active not recruiting | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Early Breast Cancer
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →